Ashish Bajel

9PUBLICATIONS
46CO-AUTHORS
Haematological tumoursHaematologyRespiratory diseasesCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Jul 26, 2026
Phase 1 clinical trial of S64315, an intravenous MCL1 inhibitor, in patients with myeloid malignancies.

|Dec 18, 2025
Reduced burden of infection with consecutive day dosing of high dose cytarabine consolidation versus conventional dosing for acute myeloid leukemia.

Alice J Liu, Emily Batterham, Rithin Nedumannil

|Jul 02, 2025
Design, implementation and evaluation of a model of care for patients with germline predisposition to haematological malignancy and bone marrow failure syndromes.

Lucy C Fox, Erin Goode, Nicole Den Elzen

|Mar 01, 2024
Targeting Molecular Measurable Residual Disease and Low-Blast Relapse in AML With Venetoclax and Low-Dose Cytarabine: A Prospective Phase II Study (VALDAC).

Ing Soo Tiong, Devendra K Hiwase, Emad Abro

|Sep 01, 2023
Consecutive day dosing of high-dose cytarabine consolidation over 3 days is resource-efficient and safe in older adult patients with acute myeloid leukemia.

Rithin Nedumannil, Emily Batterham, Emily Harding

|Aug 02, 2023
Allogeneic stem cell transplantation achieves long-term remissions in mantle cell lymphoma, including in TP53-mutated disease.

Thomas E Lew, Edward R Scheffer Cliff, Michael Dickinson

Pageof 2

Frequent Collaborators

4 joint publications

David S Ritchie

3 joint publications

Piers Blombery

3 joint publications

Rithin Nedumannil

2 joint publications

Andrew H Wei